INFO & CONTACTS:  +39 02 2390 1

A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)

Phase: Phase II clinical trials

Principal Investigator: Dott. Lo Russo Giuseppe

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: Visugromab (CTL-002)

Pathologies: Lung cancer

A phase 2b randomized, placebo-controlled, blinded clinical trial investigating the efficacy and safety of visugromab (CTL-002) in combination with carboplatin, pemetrexed, and pembrolizumab in patients with newly diagnosed metastatic non-squamous non-small cell lung cancer. The study is divided into three parts:

Part A: A non-randomized study to assess the safety of the combination of visugromab with standard treatment (carboplatin, pemetrexed, and pembrolizumab), with the determination of the Recommended Dose for Expansion (RDE).

Part B: A randomized study to compare the efficacy and safety of visugromab in combination with standard treatment (Arm A) versus placebo plus standard treatment (Arm B).

Part C: Continuation of enrollment for further evaluation of the efficacy and safety of the treatment.

The treatment includes an induction phase with carboplatin, pemetrexed, pembrolizumab, and visugromab or placebo, followed by a maintenance therapy with pembrolizumab, pemetrexed, and visugromab or placebo.

Last update: 13/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe